002219.SHE Hengkang Medical Group Co Ltd
- Market cap
- CNY 6.77B
- P/E
- 98.0x
- P/B
- 3.30x
- ROE
- 0.1%
- Dividend yield
- 1.49%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002219.SHE undervalued?
Graham numberThe Graham number of Hengkang Medical Group Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hengkang Medical Group Co Ltd fundamental analysis
No fundamental analysis for Hengkang Medical Group Co Ltd yet.
Hengkang Medical Group Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hengkang Medical Group Co Ltd
New Journey Health Technology Group Co.,LTD, together with its subsidiaries, provides medical services and pharmaceuticals products in China and internationally. The company operates regional medical centers to treat aging diseases, such as oncology, cardiovascular, cerebrovascular, and orthopedics. It is also involved in the research, development, production, and sale of medicines comprising Duyiwei capsules, Ginsengqi Astragalus and Schisandra tablets, Maiping tablets, Qia…
Full company profileHengkang Medical Group Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hengkang Medical Group Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.18B | 3.40B | 3.84B | 3.68B | 2.81B | 3.02B | 3.16B | 3.91B | 3.80B | 3.05B | 2.82B |
| Gross Profit | 783M | 1.08B | 651M | 968M | 790M | 807M | 992M | 1.17B | 1.18B | 879M | 774M |
| Operating Income | 430M | 299M | -1.30B | -2.40B | 140M | -408M | 189M | 37.7M | 162M | 276M | 246M |
| EBITDA | 586M | 717M | -688M | -1.95B | 320M | 35.3M | 487M | 342M | 452M | 402M | 175M |
| Net Income | 404M | 203M | -1.42B | -2.52B | -52.2M | -371M | 156M | 29.0M | 115M | 30.9M | 1.40M |
| EPS | 0.21 | 0.11 | -0.76 | -1.35 | -0.03 | -0.20 | 0.05 | 0.01 | 0.03 | 0.01 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 5.98B | 10.3B | 8.76B | 4.91B | 4.82B | 6.69B | 5.64B | 6.08B | 6.68B | 6.65B | 6.62B |
| Total Liabilities | 1.81B | 5.91B | 5.90B | 4.70B | 4.66B | 5.10B | 3.88B | 3.85B | 4.64B | 4.64B | 4.58B |
| Shareholders' Equity | 4.08B | 4.19B | 2.71B | 195M | 134M | 1.55B | 1.72B | 2.20B | 1.98B | 1.95B | 1.98B |
| Cash & Short-term Investments | 705M | 594M | 347M | 122M | 172M | 2.03B | 559M | 580M | 478M | 393M | 269M |
| Total Debt | 910M | 3.34B | 3.13B | 2.85B | 2.43B | 2.44B | 1.58B | 1.57B | 1.41B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -697M | -205M | 523M | 550M | 284M | 277M | 268M | 291M | 439M | 294M | - |
| Capital Expenditure | 280M | 574M | 220M | 216M | 217M | 199M | 222M | 195M | 307M | 257M | 216M |
| Free Cash Flow | -977M | -778M | 302M | 334M | 67.2M | 78.6M | 46.5M | 95.8M | 131M | 36.8M | -157M |
| Ratios | |||||||||||
| ROE | 9.9% | 4.8% | -52.3% | -1,293.4% | -39.0% | -23.9% | 9.1% | 1.3% | 5.8% | 1.6% | 0.1% |
| ROA | 6.7% | 2.0% | -16.2% | -51.3% | -1.1% | -5.6% | 2.8% | 0.5% | 1.7% | 0.5% | 0.0% |
| Net Profit Margin | 18.6% | 6.0% | -36.9% | -68.4% | -1.9% | -12.3% | 4.9% | 0.7% | 3.0% | 1.0% | 0.0% |
| Debt to Equity | 0.22x | 0.80x | 1.16x | 14.63x | 18.13x | 1.57x | 0.92x | 0.71x | 0.71x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hengkang Medical Group Co Ltd dividends
- Dividend yield
- 1.49%
- Forward dividend
- -
- Payout ratio
- 325.5%
- Ex-dividend date
- Feb 28, 2014
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 101M | 0.03 | 325.5% |
| 2024 | CNY 118M | 0.04 | 103.0% |
| 2023 | CNY 104M | 0.03 | 358.9% |
| 2022 | CNY 276M | 0.08 | 176.7% |
| 2021 | CNY 54.2M | 0.03 | - |
| 2020 | CNY 83.9M | 0.04 | - |
| 2019 | CNY 395M | 0.21 | - |
| 2018 | CNY 325M | 0.17 | - |
| 2017 | CNY 199M | 0.11 | 98.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 25:10 on Oct 28, 2015.
Who owns Hengkang Medical Group Co Ltd
- Insiders 37.02%
- Institutions 2.51%
- Public & others 60.47%
- Shares outstanding 3.45B
- Free float 2.55B
Hengkang Medical Group Co Ltd company profile
- Company name
- Hengkang Medical Group Co Ltd
- Ticker
- 002219.SHE
- ISIN
- CNE1000009R5
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Mar 6, 2008
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 8,843
- Fiscal year end
- December
- Address
- Fortune Financial Center, Beijing, China, 100020
- Phone
- 86 10 8523 5985
- Website
- njhtg.com
About Hengkang Medical Group Co Ltd
New Journey Health Technology Group Co.,LTD, together with its subsidiaries, provides medical services and pharmaceuticals products in China and internationally. The company operates regional medical centers to treat aging diseases, such as oncology, cardiovascular, cerebrovascular, and orthopedics. It is also involved in the research, development, production, and sale of medicines comprising Duyiwei capsules, Ginsengqi Astragalus and Schisandra tablets, Maiping tablets, Qianlie Antong tablets, Prosta Antong tablets, Gongliuning capsules, cough and phlegm granules, cold and flu granules, Wuhu San, Wei Funing capsules, and other proprietary Chinese medicine products. In addition, it engages in cultivation of Chinese herbal medicine; investment management; retail business; wholesale trading activities; and provision of resident services. The company was formerly known as Hengkang Medical Group Co.,Ltd. New Journey Health Technology Group Co.,LTD was founded in 2001 and is headquartered in Beijing, China.
Hengkang Medical Group Co Ltd management
5- Mr. Liu JunAccounting Supervisor & Chief Financial Officer · born 1979
- Ms. Lihua SongSenior VP & Non-Independent Director · born 1963
- Mr. Chen NieVice President · born 1967
- Mr. Xu XuVP & Secretary of the Board of Director · born 1983
- Mr. Dian ZhuVice President · born 1982